Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 109; no. 7; pp. 2346 - 2350
Main Authors Blum, Sabine, Chalandon, Yves, Labopin, Myriam, Finke, Jürgen, Gedde-Dahl, Tobias, Othman, Tarek Ben, Cornelissen, Jan J, Jindra, Pavel, Labussière-Wallet, Hélène, Collin, Matthew, Lenhoff, Stig, Kobbe, Guido, Gutiérrez, Norma C, Nagler, Arnon, Mohty, Mohamad
Format Journal Article
LanguageEnglish
Published Italy Fondazione Ferrata Storti 01.07.2024
Ferrata Storti Foundation
Subjects
Adolescent
Adult
Aged
Central Nervous System Neoplasms - therapy
Europe - epidemiology
Female
Hematopoietic Stem Cell Transplantation - methods
Humans
Incidence
Letter to the Editor
Leukemia, Myeloid, Acute - therapy
Male
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology
Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Recurrence
Treatment Outcome
Young Adult
Europe
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 23
Disclosures
SB, YC and ML wrote the manuscript. ML performed statistical analyses. AN and MM revised the manuscript. SB, YC, JF, TGD, TBO, JJC, PJ, HLW, MC, SL, GK, NCG, AN and MM provided patients and patient follow-up. All authors approved the manuscript before submission.
Contributions
YC reports consulting fees from MSD, Novartis, Incyte, BMS, Pfizer, Abbvie, Roche, Jazz, Gilead, Amgen, Astra-Zeneca, and Servier, and travel support from MSD, Roche, Gilead, Amgen, Incyte, Abbvie, Janssen, Astra-Zeneca, and Jazz. GK reports an Advisory Role or Speaker Honoraria from MSD, Pfizer, Amgen, Novartis, Gilead, BMS-Celgene, Abbvie, Biotest, Takeda, Eurocept, and JAZZ, and Financing of Scientific Research from BMS-Celgene, Amgen, Abbvie, Medac and Eurocept. None of the other authors have any conflicts of interest to disclose.
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2023.284858